JP2015519313A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519313A5
JP2015519313A5 JP2015507425A JP2015507425A JP2015519313A5 JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5 JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
composition according
amino acid
fviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015507425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519313A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/055107 external-priority patent/WO2013160005A1/en
Publication of JP2015519313A publication Critical patent/JP2015519313A/ja
Publication of JP2015519313A5 publication Critical patent/JP2015519313A5/ja
Withdrawn legal-status Critical Current

Links

JP2015507425A 2012-04-24 2013-03-13 血友病の治療に適する医薬組成物 Withdrawn JP2015519313A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12165296.0 2012-04-24
EP12165296 2012-04-24
US201261641439P 2012-05-02 2012-05-02
US61/641,439 2012-05-02
EP13150575.2 2013-01-09
EP13150575 2013-01-09
US201361752614P 2013-01-15 2013-01-15
US61/752,614 2013-01-15
PCT/EP2013/055107 WO2013160005A1 (en) 2012-04-24 2013-03-13 Pharmaceutical composition suitable for treatment of haemophilia

Publications (2)

Publication Number Publication Date
JP2015519313A JP2015519313A (ja) 2015-07-09
JP2015519313A5 true JP2015519313A5 (https=) 2016-04-14

Family

ID=49482214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507425A Withdrawn JP2015519313A (ja) 2012-04-24 2013-03-13 血友病の治療に適する医薬組成物

Country Status (5)

Country Link
US (2) US20150045303A1 (https=)
EP (1) EP2841091A1 (https=)
JP (1) JP2015519313A (https=)
CN (1) CN104411323A (https=)
WO (1) WO2013160005A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AR101060A1 (es) * 2014-02-12 2016-11-23 Novo Nordisk As Conjugados de fviii
EP3152230B1 (en) 2014-06-06 2019-08-07 Octapharma AG Preparation comprising factor viii and von willebrand factor peptides
WO2016198521A1 (en) 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
CA3043397A1 (en) * 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
KR20200018690A (ko) * 2017-06-22 2020-02-19 체에스엘 베링 렝나우 아게 절단된 vwf에 의한 fviii 면역원성의 조절
CN108918235A (zh) * 2018-05-16 2018-11-30 绍兴文理学院 一种肿瘤淋巴结离体标本的固定处理方法
CN108753910A (zh) * 2018-05-16 2018-11-06 浙江思格医疗科技有限公司 一种消化液
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
US12252528B2 (en) 2018-10-23 2025-03-18 The Children's Hospital Of Philadelphia Compositions and methods for modulating Factor VIII function
CN114072420B (zh) * 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
EP4013389A1 (en) 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
ES2392569T3 (es) * 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
KR101582841B1 (ko) * 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 viii 분자
CA2740793A1 (en) 2008-11-03 2010-06-03 Haiyan Jiang Method for the treatment of hemophilia
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
CN105153313A (zh) 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー/エス 安定化させた第viii因子バリアント
EP2616486B1 (en) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake

Similar Documents

Publication Publication Date Title
JP2015519313A5 (https=)
AR081042A1 (es) Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g
BR112021022315A2 (pt) Ligantes de peptídeo bicíclicos específicos para ox40
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
JP2012522529A5 (https=)
UA116632C2 (uk) Химерний білок, який містить фактор viii та фактор віллебранда, і його застосування
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
AR108453A1 (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia del factor de necrosis tumoral (tnf) y un resto de unión a proteína transmembrana monomérica de tipo 1 (pd1)
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
WO2013036778A3 (en) Compstatin analogs with improved pharmacokinetic properties
HRP20240640T1 (hr) Kimerni proteini faktora viii i njihova upotreba
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HRP20161305T1 (hr) Liječenje mikrobnih infekcija
JP2017523781A5 (https=)
JP2013519698A5 (https=)
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2015532307A5 (https=)
NZ701205A (en) Optimised subcutaneous therapeutic agents
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
JP2012102105A5 (https=)
EP4424366A3 (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
WO2015054439A3 (en) Hybrid factor viii polypeptides for use to treat hemophilia a
JP2017523783A5 (https=)
EP3556857A3 (en) Cdc45l peptides and vaccines including the same